Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Deep Brain Stimulation of the Cortico-Striato-Thalamo-Cortical Network May Be an Option for Refractory OCD
    ABSTRACT & COMMENTARY

    Deep Brain Stimulation of the Cortico-Striato-Thalamo-Cortical Network May Be an Option for Refractory OCD

    July 1, 2020
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Deep Brain Stimulation (DBS) Is a safe and Effective Treatment for Medically Refractory Essential Tremor

    Moving in the Right Direction: Deep Brain Stimulation for PD

    Deep Brain Stimulation in the Pedunculopontine Nucleus Area in Parkinson's Disease

    Related Products

    Selective Disruption of Thalamo-Cortical Connections in Patients with Disorders of Consciousness

    Electrical Brain Stimulation for Primary Progressive Aphasia

    Keywords

    Depression

    brain

    efficacy

    stimulation

    deep

    By Harini Sarva, MD

    Assistant Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Sarva reports that she is a consultant for Accorda Therapeutics, Amneal Pharmaceuticals, and Merz Pharma.

    SYNOPSIS: Deep brain stimulation can be a treatment option for refractory obsessive-compulsive disorder, but the results are not significantly better than lesioning procedures. Small sample sizes, diverse targets of stimulation, and inconsistencies in rating scales are limiting factors in the studies of this modality.

    SOURCE: Martinho FP, Duarte GS, Simoes de Couto F. Efficacy, effect on mood symptoms, and safety of deep brain stimulation in refractory obsessive-compulsive disorder: A systematic review and meta-analysis. J Clin Psychiatry 2020;81:19r12821.

    This was a systematic review and meta-analysis of the available studies assessing the efficacy of deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). While selective serotonin reuptake inhibitors and cognitive behavioral therapy remain first-line therapies, a small percentage of OCD patients require surgical intervention. The cortico-striato-thalamo-cortical network is targeted based on benefits seen in earlier lesioning procedures. Randomized clinical trials (RCTs) and observational studies, which enrolled OCD patients for DBS, were included. Primary measures included the Yale Brown Obsessive Compulsive Scale (Y-BOCS) and serious adverse events. Secondary measures included proportion of patients with complete response (Y-BOCS decrease by > 35%); proportion of patients in remission (Y-BOCS < 6); proportion of patients with a mood response; adverse events; dropouts; and predictors of response.

    A search in EMBASE and other portals led to 1,817 papers being evaluated, and they were further narrowed by the authors to 46 papers. Eight were RCTs and 38 were observational studies, 13 of which were case reports. There was a total of 225 patients from these studies, and 46% were women. Average follow-up was 33 months. Limbic structures were stimulated in 33 studies, with the most common site being the subthalamic nucleus (STN); 42 reported bilateral DBS. Among the RCTs, 51% had complete response, with 57% of all subjects exhibiting a complete response to DBS. Only 8% of subjects in RCTs had achieved remission, with an overall remission rate of 5%. Among the different variables studied, the most consistent correlation was found between response in Y-BOCS and response in depression. Among the RCTs, there was a significant reduction in the weighted depression scores. There were 814 adverse events; 289 were psychiatric (the most common were hypomania, sleep issues, and irritability) and 202 were neurologic adverse effects (the most common were paresthesias, cognitive issues, and headache).

    COMMENTARY

    DBS has revolutionized treatment of various movement disorders, including Parkinson’s disease (PD), essential tremor, and dystonia. Its use is increasing in psychiatric disorders, such as OCD, which has demonstrated promise with more than 200 patients having the surgery, resulting in reduction in Y-BOCS scores. However, the overall results are only slightly better than lesional procedures. Therefore, for those seeking surgical intervention without implanted hardware, lesional procedures, such as capsulotomy, still may be a viable option. In addition, the targets have been diverse. No significant difference was found in efficacy between limbic and non-limbic targets, suggesting that the pathways are quite extensive and that targeting any region of these pathways can have an effect on OCD. However, the wide array of targets also leads to a greater side effect profile and difficulty in determining the most effective target. The listed neuropsychiatric side effects were not surprising, but because the vast majority of targets are smaller than for PD and other movement disorders, close monitoring for stimulation-related side effects is warranted. Limitations in the scale scores and the lack of streamlined scales for depression in this meta-analysis are other limiting factors. Further studies, with larger sample sizes and greater follow-up, are needed to determine the true efficacy of DBS in OCD and the role of treating depression on the total OCD response rates.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 39, No. 11) - July 2020
    July 1, 2020

    Table Of Contents

    A Population-Based View into the Incidence and Etiology of Papilledema

    Epilepsy 2020: At the Crossroads of Telemedicine and Smartphone Technology

    Preventing and Treating Medication Overuse Headache

    Deep Brain Stimulation of the Cortico-Striato-Thalamo-Cortical Network May Be an Option for Refractory OCD

    MRI and Clinical Correlation in Lumbar Arachnoiditis

    Endovascular Treatment for Acute Basilar Artery Occlusion Is Safe and Effective

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin;
    Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial
    relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing